阿德福韦酯联合拉米夫定治疗乙肝肝硬化失代偿期的疗效分析  

Curative effect analysis of adefovir dipivoxil and lamivudine in the treatment of decompensated hepatitis B cirrhosis period

作　　者：孟玉丽[1] 张红旭[1] 黄俊红[2] 

机构地区：[1]漯河医学高等专科学校一附院肝病科,462000 [2]漯河医学高等专科学校一附院神经外二科,462000

出　　处：《中国实用医药》2015年第20期26-27,共2页China Practical Medicine

摘　　要：目的分析阿德福韦酯联合拉米夫定治疗乙型肝炎(乙肝)肝硬化失代偿期的疗效。方法 80例乙肝肝硬化失代偿期患者,将其随机分为对照组和治疗组,各40例,两组患者均实行保肝、利尿等基础治疗,对照组患者在实行基础治疗的同时服用拉米夫定,而治疗组则在基础治疗的同时服用阿德福韦酯和拉米夫定。观察治疗3个月后两组的肝功能和出凝血时间变化情况。结果两组患者经过治疗后,肝功能和出凝血时间均得到有效改善,同时治疗组的疗效明显优于对照组(P<0.05),两组治疗后均未出现不良反应。结论阿德福韦酯联合拉米夫定治疗乙肝肝硬化失代偿期的疗效显著,安全可靠,值得进一步推广应用。Objective To analyze curative effect by adefovir dipivoxil and lamivudine in the treatment of decompensated hepatitis B cirrhosis period. Methods A total of 80 patients with decompensated hepatitis B cirrhosis period were randomly divided into control group and treatment group, with 40 cases in each group. Both groups received basic treatment of liver protection and dieresis, and the control group received additional lamivudine, while the treatment group received additional combination of adefovir dipivoxil and lamivudine. Changes of liver function and bleeding and coagulation time of the two groups were observed after 3 months of treatment. Results Both groups had effectively improved liver function and bleeding and coagulation time after treatment. The treatment group had much better curative effect than the control group（P0.05）. There was no adverse reactions in both groups after treatment. Conclusion Combination of adefovir dipivoxil and lamivudine provides remarkable curative effect in treating decompensated hepatitis B cirrhosis period. This method is safe and reliable, and it is worthy of further promotion and application.

关 键 词：乙型肝炎 肝硬化失代偿期 阿德福韦酯 拉米夫定 

分 类 号：R512.62[医药卫生—内科学]